Creutzig U - Search Results

1

AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity.

Creutzig U, Reinhardt D, Diekamp S, Dworzak M, Stary J, Zimmermann M. Creutzig U, et al. Leukemia. 2005 Aug;19(8):1355-60. doi: 10.1038/sj.leu.2403814. Leukemia. 2005. PMID: 15920490 Clinical Trial.

2

Myelodysplasia and acute myelogenous leukemia in Down's syndrome. A report of 40 children of the AML-BFM Study Group.

Creutzig U, Ritter J, Vormoor J, Ludwig WD, Niemeyer C, Reinisch I, Stollmann-Gibbels B, Zimmermann M, Harbott J. Creutzig U, et al. Leukemia. 1996 Nov;10(11):1677-86. Leukemia. 1996. PMID: 8892666

3

The role of intensive AML-specific therapy in treatment of children with RAEB and RAEB-t.

Creutzig U, Bender-Götze C, Ritter J, Zimmermann M, Stollmann-Gibbels B, Körholz D, Niemeyer C. Creutzig U, et al. Leukemia. 1998 May;12(5):652-9. doi: 10.1038/sj.leu.2400987. Leukemia. 1998. PMID: 9593261

4

Duration of first remission predicts remission rates and long-term survival in children with relapsed acute myelogenous leukemia.

Stahnke K, Boos J, Bender-Götze C, Ritter J, Zimmermann M, Creutzig U. Stahnke K, et al. Among authors: creutzig u. Leukemia. 1998 Oct;12(10):1534-8. doi: 10.1038/sj.leu.2401141. Leukemia. 1998. PMID: 9766496

5

Idarubicin improves blast cell clearance during induction therapy in children with AML: results of study AML-BFM 93. AML-BFM Study Group.

Creutzig U, Ritter J, Zimmermann M, Hermann J, Gadner H, Sawatzki DB, Niemeyer CM, Schwabe D, Selle B, Boos J, Kühl J, Feldges A. Creutzig U, et al. Leukemia. 2001 Mar;15(3):348-54. doi: 10.1038/sj.leu.2402046. Leukemia. 2001. PMID: 11237056 Clinical Trial.

6

Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Münster 93.

Creutzig U, Ritter J, Zimmermann M, Reinhardt D, Hermann J, Berthold F, Henze G, Jürgens H, Kabisch H, Havers W, Reiter A, Kluba U, Niggli F, Gadner H. Creutzig U, et al. J Clin Oncol. 2001 May 15;19(10):2705-13. doi: 10.1200/JCO.2001.19.10.2705. J Clin Oncol. 2001. PMID: 11352963 Clinical Trial.

7

Isolated myelosarcoma in children--update and review.

Reinhardt D, Creutzig U. Reinhardt D, et al. Among authors: creutzig u. Leuk Lymphoma. 2002 Mar;43(3):565-74. doi: 10.1080/10428190290012056. Leuk Lymphoma. 2002. PMID: 12002760 Review.

8

Infectious complications in pediatric acute myeloid leukemia: analysis of the prospective multi-institutional clinical trial AML-BFM 93.

Lehrnbecher T, Varwig D, Kaiser J, Reinhardt D, Klingebiel T, Creutzig U. Lehrnbecher T, et al. Among authors: creutzig u. Leukemia. 2004 Jan;18(1):72-7. doi: 10.1038/sj.leu.2403188. Leukemia. 2004. PMID: 14586478

9

Prognostic relevance of risk groups in the pediatric AML-BFM trials 93 and 98.

Creutzig U, Reinhardt D, Zimmermann M; AML-BFM Study Group. Creutzig U, et al. Ann Hematol. 2004;83 Suppl 1:S112-6. doi: 10.1007/s00277-004-0850-2. Ann Hematol. 2004. PMID: 15124699 No abstract available.

10

Acute megakaryoblastic leukemia in children and adolescents, excluding Down's syndrome: improved outcome with intensified induction treatment.

Reinhardt D, Diekamp S, Langebrake C, Ritter J, Stary J, Dworzak M, Schrauder A, Zimmermann M, Fleischhack G, Ludwig WD, Harbott J, Creutzig U. Reinhardt D, et al. Among authors: creutzig u. Leukemia. 2005 Aug;19(8):1495-6. doi: 10.1038/sj.leu.2403815. Leukemia. 2005. PMID: 15920489 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

252 results

Search Page